Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons
Human Molecular Genetics · 19.06.2023 · 32 (13) · 2192-2204
DOI: 10.1093/hmg/ddad048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 03.04.2023. Verfasst von R Asadollahi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland. Hauptthemen laut MEDLINE: Epilepsy, Intellectual Disability. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation, University of Zurich Clinical Research Priority Program, University Research Priority Program of the University of Zurich.
Abstract (Originalsprache)
Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel NaV1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that NaV1.2 channel gain-of-function typically causes epilepsy, whereas loss-of-function leads to ID/autism. How altered channel biophysics translate into patient neurons remains unknown. Here, we investigated iPSC-derived early-stage cortical neurons from ID patients harboring diverse pathogenic SCN2A variants [p.(Leu611Valfs*35); p.(Arg937Cys); p.(Trp1716*)] and compared them with neurons from an epileptic encephalopathy (EE) patient [p.(Glu1803Gly)] and controls. ID neurons consistently expressed lower NaV1.2 protein levels. In neurons with the frameshift variant, NaV1.2 mRNA and protein levels were reduced by ~ 50%, suggesting nonsense-mediated decay and haploinsufficiency. In other ID neurons, only protein levels were reduced implying NaV1.2 instability. Electrophysiological analysis revealed decreased sodium current density and impaired action potential (AP) firing in ID neurons, consistent with reduced NaV1.2 levels. In contrast, epilepsy neurons displayed no change in NaV1.2 levels or sodium current density, but impaired sodium channel inactivation. Single-cell transcriptomics identified dysregulation of distinct molecular pathways including inhibition of oxidative phosphorylation in neurons with SCN2A haploinsufficiency and activation of calcium signaling and neurotransmission in epilepsy neurons. Together, our patient iPSC-derived neurons reveal characteristic sodium channel dysfunction consistent with biophysical changes previously observed in heterologous systems. Additionally, our model links the channel dysfunction in ID to reduced NaV1.2 levels and uncovers impaired AP firing in early-stage neurons. The altered molecular pathways may reflect a homeostatic response to NaV1.2 dysfunction and can guide further investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
- Faculty of Engineering and Science, University of Greenwich London, Medway Campus, Chatham Maritime ME4 4TB, UK.
- Department of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.
- Neuroscience Center Zurich, University of Zurich, Zurich 8057, Switzerland.
- Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
- Department of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
Förderung
- Swiss National Science Foundation
- University of Zurich Clinical Research Priority Program
- University Research Priority Program of the University of Zurich
- European Research Council Starting
- Bavarian Ministry of Education and Culture, Science
Zitieren
APA
Asadollahi, R., Delvendahl, I., Muff, R., Tan, G., Rodríguez, D. G., Turan, S., Russo, M., Oneda, B., Joset, P., Boonsawat, P., Masood, R., Mocera, M., Ivanovski, I., Baumer, A., Bachmann-Gagescu, R., Schlapbach, R., Rehrauer, H., Steindl, K., Begemann, A., …, & Rauch, A. (2023). Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons. Human Molecular Genetics, 32(13), 2192-2204. https://doi.org/10.1093/hmg/ddad048
Vancouver
Asadollahi R, Delvendahl I, Muff R, Tan G, Rodríguez DG, Turan S, et al. Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons. Human Molecular Genetics. 2023;32(13):2192-2204. doi:10.1093/hmg/ddad048
BibTeX
@article{Asadollahi2023,
author = {Asadollahi, R and Delvendahl, I and Muff, R and Tan, G and Rodríguez, D G and Turan, S and Russo, M and Oneda, B and Joset, P and Boonsawat, P and Masood, R and Mocera, M and Ivanovski, I and Baumer, A and Bachmann-Gagescu, R and Schlapbach, R and Rehrauer, H and Steindl, K and Begemann, A and Reis, A and Winkler, J and Winner, B and Müller, M and Rauch, A},
title = {Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons},
journal = {Human Molecular Genetics},
year = {2023},
volume = {32},
number = {13},
pages = {2192--2204},
doi = {10.1093/hmg/ddad048}
}
EUVIMED